Blog

by Heidi Hagen and Christophe Suchet | February 21, 2020
This post is the eighth in an eight-part series on data management strategies for personalized therapeutics, such as cell therapies, gene therapies, or neoantigen cancer vaccines.

by Heidi Hagen and Christophe Suchet | February 19, 2020
This post is the seventh in an eight-part series on data management strategies for personalized therapeutics, such as cell therapies, gene therapies, or neoantigen cancer vaccines.

by Heidi Hagen and Christophe Suchet | February 12, 2020
This post is the sixth in an eight-part series on data management strategies for personalized therapeutics, such as cell therapies, gene therapies, or neoantigen cancer vaccines.

by Heidi Hagen and Christophe Suchet | February 11, 2020
This post is the fifth in an eight-part series on data management strategies for personalized therapeutics, such as cell therapies, gene therapies, or neoantigen cancer vaccines.

by Marc Puich | November 15, 2019
At Biomanufacturing World Summit this week, leaders at the forefront of producing cell and gene therapies gathered to talk about what’s really required to produce deeply individualized therapeutics at scale. Here are a few of the highlights:

Subscribe to our blog
Required
Required
Required
Required
Required
Required
Required
Required